At 14 days, expanded B cells were incubated with autologous T cells isolated from the same MN patient alone or in the presence of 3 μg/mL BiAATE or 3 μg/mL blinatumomab (BLINA), an anti-CD3 and anti-CD19 bispecific antibody approved for the treatment of refractory B cell precursor acute lymphoblastic leukemia. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.